Sevoflurane In Acute Myocardial Infarction (SIAMI)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00971607|
Recruitment Status : Completed
First Posted : September 3, 2009
Last Update Posted : September 9, 2014
Ischemic postconditioning can reduce myocardial injury following myocardial infarction.
A potential pharmacological agent is the anesthetic Sevoflurane. The investigators' hypothesis is that sevoflurane during primary percutaneous coronary intervention (PCI) will reduce infarct size.
|Condition or disease||Intervention/treatment||Phase|
|Acute Myocardial Infarction||Drug: Oxygen + Sevoflurane Drug: Oxygen (placebo)||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||50 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Sevoflurane Sedation During Primary Percutaneous Coronary Intervention.|
|Study Start Date :||May 2009|
|Actual Primary Completion Date :||December 2013|
|Actual Study Completion Date :||December 2013|
Active Comparator: 1
Drug: Oxygen + Sevoflurane
Oxygen with end-tidal MAC of Sevoflurane 0.5 during PCI.
Placebo Comparator: 2
Drug: Oxygen (placebo)
Control will receive oxygen only.
- Infarct size by area under the curve of cardiac markers. [ Time Frame: 3 days ]
- Left ventricular function. [ Time Frame: Six month ]
- ST segment elevation resolution [ Time Frame: 90 minutes ]
- TIMI flow [ Time Frame: 60 minutes ]
- Renal function [ Time Frame: 48 hours ]
- CRP [ Time Frame: 24 hours ]
- Patient satisfaction [ Time Frame: 1 hour ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00971607
|London Health Sceinces Centre|
|London, Ontario, Canada, N6A5A5|
|Principal Investigator:||Shahar Lavi, MD||Lawson Health Research Institute|